Results 61 to 70 of about 1,344,051 (191)

Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis [PDF]

, 2004
ObjectiveThe purpose of this study was to assess which clinical features of patients with myasthenia gravis predict postoperative respiratory problems due to myasthenic crisis after transsternal thymectomy.MethodsOne hundred twenty-two patients who ...
Mawatari, Tohru, Abe, Tomio, Watanabe, Toshiaki, Kusajima, Katsuyuki, Takahashi, Noriyuki, Watanabe, Atsushi, Obama, Takuro, Ohsawa, Hisayoshi, Ichimiya, Yasunori   +8 more
core   +1 more source

Emotional stress as a trigger of myasthenic crisis and concomitant takotsubo cardiomyopathy: a case report

Journal of Medical Case Reports, 2010
Introduction Myasthenia gravis is a neuromuscular junction post-synaptic autoimmune disorder. Myasthenic crisis is characterized by respiratory failure requiring mechanical ventilation.
Levine Reed, Wang JingTian, Beydoun Said R, Farvid Ali   +3 more
doaj   +1 more source

Myasthenic crisis as the first presentation of myasthenia gravis: A case report [PDF]

, 2021
Myasthenic crisis is a condition characterized by the sudden onset of myasthenic weakness involving the respiratory muscles and requires ventilatory support to prevent death.
Leong Jia Qian, Azman Ali Raymond, Azliza Ibrahim, Justin Leow Wen Hsiang, Alvin Oliver Payus   +4 more
core   +2 more sources

Myasthenia Gravis and Thymoma

Muscle &Nerve, Volume 74, Issue 4, Page 1156-1173, October 2026.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

Crisis pregnancy and pregnancy decision making: An outline of influencing factors [PDF]

, 2004
This document aims to review research literature in order to: • outline and describe the factors that have been demonstrated to affect the level and incidence of crisis pregnancy • examine the factors that affect a woman’s decision when faced with a ...
O’Keeffe, Stephanie
core  

Clinical Variability and Genotype‐Driven Outcomes in CHRND‐Related Congenital Myasthenic Syndrome

European Journal of Neurology, Volume 33, Issue 9, September 2026.
Clinical variability in CHRND‐related congenital myasthenic syndrome ranges from isolated ocular involvement to severe neonatal‐onset disease with respiratory insufficiency. In a multicenter cohort of nine patients, ocular symptoms represented the core phenotype, while disease severity was influenced by genotype and presumed residual acetylcholine ...
David Muhmann, Göknur Haliloğlu, Maria Antonia Grimalt, Damjan Osredkar, Ana Vesperinas Castro, Silvia Cerezo Corredera, Angela Abicht, Adalet Elçin Yıldız, Johann Böhm, Ulrike Schara‐Schmidt, Anja Troha Gergeli, Berta Estevez‐Arias, Elena Cortes Vicente, Andres Nascimento, Adela Della Marina, Daniel Natera‐de Benito, Andreas Roos   +16 more
wiley   +1 more source

Distinguishing Myasthenia Exacerbation from Severe Preeclampsia: A Diagnostic and Therapeutic Challenge [PDF]

Journal of Clinical and Diagnostic Research, 2015
Myasthenia gravis is an acquired, autoimmune neuromuscular disorder characterized by voluntary muscle weakness. Pregnant patients may have disease exacerbation, respiratory failure, crisis, adverse drug reaction, surprisingly enough remission at any ...
Pooja Sikka, Bharti Joshi, Neelam Aggarwal, Vanita Suri, Hement Bhagat   +4 more
doaj   +1 more source

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper

European Journal of Neurology, Volume 33, Issue 9, September 2026.
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Andreas Meisel, Adela Della Marina, Paolo Doksani, Tim Hagenacker, Christoph Kleinschnitz, Heidrun H. Krämer, Jan D. Lünemann, Sven G. Meuth, Tobias Ruck, Ulrike Schara‐Schmidt, Christiane Schneider‐Gold, Benedikt Schoser, Michael Schroeter, Charlotte Schubert, Jörn Peter Sieb, Fritz Zimprich, Jana Zschüntzsch, Sarah Hoffmann   +17 more
wiley   +1 more source

Serum 25-hydroxy vitamin D, vitamin B12 and folic acid levels in myasthenic crisis

, 2022
Aim: Myasthenia gravis (MG) is an autoimmune disease often caused by autoantibodies against postsynaptic acetylcholine receptors (AChR). It is known that vitamin D (VD), vitamin B12 and folic acid have some effects on the immune system.
Caner BAYDAR, YEVGİ, Recep, Recep YEVGİ, BAYDAR, CANER   +3 more
core   +1 more source

Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis

Muscle &Nerve, Volume 74, Issue 2, Page 422-426, August 2026.
ABSTRACT Introduction/Aims Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six‐week cyclic regimen may be associated with a “wearing‐off” effect and disease fluctuations. We evaluated the non‐cyclic administration
Marc Abi Aoun, Diane Beauvais, Marlène Barnay, Marie‐Hélène Violleau, Stéphane Mathis, Fanny Duval, Guilhem Sole   +6 more
wiley   +1 more source